Clinical trial · Observational
The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss
The Development and Pilot Testing of a New Magnetic Resonance (MR) Imaging Protocol to Quantify Both Myeloma Disease Burden and Associated Bone Loss
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In the proposed study, the investigators will aim to develop and pilot a Magnetic Resonance (MR) imaging protocol and assess its ability to achieve the following: quantification of tumour burden and bone loss, detecting longitudinal changes in tumour load with therapy and detecting longitudinal changes in microarchitecture with therapy. The investigators also aim to investigate whether bone loss is better, worse or the same with different imaging techniques. This will be investigated by correlating the DXA imaging data with Diffusion-Weighted Magnetic Resonance Imaging (DWMRI) to see if it is possible to achieve quantifiable data of bone density.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Monoclonal Gammopathy of Undetermined Significance (MGUS) | Monoclonal Gammopathy of Undetermined Significance | ALIAS | 0.90 |
| Myeloma | Multiple Myeloma | ALIAS | 0.90 |
| Smouldering Myeloma | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bloods and urine | Other | — | UNRESOLVED |
| Diffusion Weighted Magnetic Resonance Imaging (DWMRI) | Other | — | UNRESOLVED |
| DXA scan | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Group 1- Myeloma
- description
- Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests. This will be repeated at 6 months.
- interventionNames
- Other: Diffusion Weighted Magnetic Resonance Imaging (DWMRI)
- Other: DXA scan
- Other: Bloods and urine
- label
- Group 2- MGUS
- description
- Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests. This will be repeated at 6 months.
- interventionNames
- Other: Diffusion Weighted Magnetic Resonance Imaging (DWMRI)
- Other: DXA scan
- Other: Bloods and urine
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria (All Groups): * Participant is able to and willing to give informed consent for participation in the study. * Male or Female, aged 18 years or above. Inclusion Criteria (Groups 1 and 2): * Newly diagnosed myeloma or newly relapsed myeloma eligible for next therapy. * Smouldering myeloma or intermediate or high risk MGUS. * Patients attending Oxford NHS Haematology-Oncology centre. * Diagnoses of MGUS, Smouldering Myeloma and MM made in accordance with the clinical diagnostic criteria set forth by IMWG (International Myeloma Working Group). Exclusion Criteria (All Groups): * Those who are unable or unwilling to give informed consent. * Women who may be pregnant, breast feeding or women of child-bearing potential who are unwilling or unable to take sufficient precautionary measures will be excluded due to DXA imaging. Exclusion Criteria (Groups 1 and 2): * Signs of Spinal Cord Compression. * Patients with documented metastatic lesions from another type of malignancy. * Known contraindication for a MRI scan, including unacceptable pain on lying flat for 1 hour.
References
Publications (0)
Data not yet available